The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study
Abstract
OBJECTIVE: To evaluate the safety and efficacy of once daily doses of tenofovir DF (TDF) administered in combination with other antiretroviral therapy (ART) in treatment-experienced HIV-1-infected patients with incomplete virological suppression. DESIGN: One-hundred and eighty-nine subjects with plasma HIV-1 RNA levels between 400 and 100,000 copies/ml and stable ART (> or = 8 weeks) were randomized (2 : 2 : 2 : 1 ratio) to add TDF 75 mg, 150 mg, or 300 mg or placebo to existing ART in a double-blinded manner. After 24 weeks, patients initially randomized to placebo received blinded TDF 300 mg. METHODS: Efficacy was analyzed by the mean changes HIV-1 RNA levels (log10 copies/ml plasma; DAVG(xx)) from week 0 to weeks 4, 24, and 48. Safety was analyzed by incidence of grade 3 or 4 clinical and laboratory adverse events. RESULTS: At baseline, patients had mean 4.6 years prior ART use with 94% having HIV-1 with nucleoside-associated resistance mutations. There were statistically significant decreases in DAVG(4) and DAVG(24) for all doses of TDF compared with placebo, with the greatest effect seen with TDF 300 mg (DAVG(4), -0.62, P < 0.001; DAVG(24), -0.58; P < 0.001; DAVG(48), -0.62). The incidence of adverse events was similar among the TDF groups and placebo through week 24. Throughout the 48-week study, no significant changes in renal function were observed. CONCLUSIONS: In treatment-experienced patients with baseline nucleoside resistance mutations, TDF provided dose-related, durable reductions in HIV-1 RNA. Through 24 weeks, the safety profile of TDF was similar to that of placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shirasaka, T., Kavlick, M. F., Ueno, T., Gao, W. Y., Kojima, E., Alcaide, M. L., Chokekijchai, S., Roy, B. M., Arnold, E., & Yarchoan, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.6.2398 · Cited by 386
Balzarini, J., Holy, A., Jindrich, J., Naesens, L., Snoeck, R., Schols, D., & De Clercq, E. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.2.332 · Cited by 350
Barditch-Crovo, P., Deeks, S. G., Collier, A., Safrin, S., Coakley, D. F., Miller, M., Kearney, B. P., Coleman, R. L., Lamy, P. D., Kahn, J. O., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2733-2739.2001 · Cited by 330
Self-citationDeGruttola, V., Dix, L., D'Aquila, R., Holder, D., Phillips, A., Ait-Khaled, M., Baxter, J., Clevenbergh, P., Hammer, S., Harrigan, R., et al. (2000) · Antiviral Therapy · doi:10.1177/135965350000500112 · Cited by 326
Self-citationIn vitro Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA
Wainberg, M. A., Miller, M. D., Quan, Y., Salomon, H., Mulato, A. S., Lamy, P. D., Margot, N. A., Anton, K. E., & Cherrington, J. M. (1999) · Antiviral Therapy · doi:10.1177/135965359900400205 · Cited by 247
Self-citationMargot, N., Isaacson, E., McGowan, I., Cheng, A., Schooley, R. T., & Miller, M. D. (2002) · AIDS · doi:10.1097/00002030-200206140-00004 · Cited by 146
Self-citation
Cited by
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Gupta, S. K., Eustace, J. A., Winston, J. A., Boydstun, I. I., Ahuja, T. S., Rodriguez, R. A., Tashima, K. T., Roland, M., Franceschini, N., Palella, F. J., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/430257 · Cited by 581
Cooper, R. D., Wiebe, N., Smith, N., Keiser, P., Naicker, S., & Tonelli, M. (2010) · Clinical Infectious Diseases · doi:10.1086/655681 · Cited by 565
Tenofovir Disoproxil Fumarate: Clinical Pharmacology and Pharmacokinetics
Kearney, B. P., Flaherty, J. F., & Shah, J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443090-00003 · Cited by 456
Antiviral Drug-Induced Nephrotoxicity
Izzedine, H., Launay-Vacher, V., & Deray, G. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.02.010 · Cited by 423
Metadata
- Authors
- Schooley, R. T., Ruane, P., Myers, R. A., Beall, G., Lampiris, H., Berger, D., Chen, S.-S., Miller, M. D., Isaacson, E., & Cheng, A. K.
- Venue
- AIDS
- Published
- 2002-06
- Volume
- 16
- Issue
- 9
- Pages
- 1257-1263
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W1996313031
- Cited by
- 270
- References
- 6
- FWCI
- 18.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. https://app.cochat.ai/papers/10.1097/00002030-200206140-00008
- The paper
- Schooley, R. T., Ruane, P., Myers, R. A., Beall, G., Lampiris, H., Berger, D., Chen, S.-S., Miller, M. D., Isaacson, E., & Cheng, A. K. (2002). Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. https://doi.org/10.1097/00002030-200206140-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.